Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetReceivables - OtherRevenue - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Perspective Therapeutics (CATX) Shares Outstanding (2016 - 2026)

Perspective Therapeutics' Shares Outstanding history spans 16 years, with the latest figure at $114.0 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding rose 53.97% to $114.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $114.0 million, a 53.97% increase, with the full-year FY2025 number at $74.3 million, up 5.19% from a year prior.
  • Shares Outstanding hit $114.0 million in Q1 2026 for Perspective Therapeutics, up from $74.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding for CATX hit a ceiling of $142.1 million in Q3 2022 and a floor of $14.2 million in Q4 2022.
  • Historically, Shares Outstanding has averaged $72.2 million across 5 years, with a median of $70.7 million in 2024.
  • Biggest five-year swings in Shares Outstanding: tumbled 89.99% in 2022 and later skyrocketed 150.78% in 2024.
  • Tracing CATX's Shares Outstanding over 5 years: stood at $14.2 million in 2022, then skyrocketed by 98.3% to $28.2 million in 2023, then skyrocketed by 150.78% to $70.7 million in 2024, then increased by 5.19% to $74.3 million in 2025, then soared by 53.38% to $114.0 million in 2026.
  • Business Quant data shows Shares Outstanding for CATX at $114.0 million in Q1 2026, $74.3 million in Q4 2025, and $74.3 million in Q3 2025.